https://www.selleckchem.com/products/k-975.html
33/45 (73%, 95% CI 58 to 85) cited knowledge of at least one cannabis-based product and 27/45 (60%, 95% CI 44 to 74) indicated at least one condition that had evidence of efficacy. 36/44 (82%, 95% CI 67 to 92) expressed future prescribing concerns but all were willing to use a cannabis-based product developed with traditional medical provenance. In the oncology setting, patients are asking doctors about symptomatic and curative treatment with cannabis-based products. Doctors are not biased against the use of products showing medical prove
Like
Comment
Share